{"id":"orca-t","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, Orca-T prevents the interaction between PD-1 and its ligands, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively. This mechanism is thought to be responsible for the drug's anti-tumor activity.","oneSentence":"Orca-T is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:54.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT05316701","phase":"PHASE3","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2022-06-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":187},{"nctId":"NCT07216443","phase":"PHASE2","title":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2025-12-09","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia","enrollment":80},{"nctId":"NCT06551584","phase":"PHASE1","title":"Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT","status":"RECRUITING","sponsor":"Stanford University","startDate":"2025-12-01","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":24},{"nctId":"NCT07346105","phase":"","title":"Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Orca Biosystems, Inc.","startDate":"","conditions":"Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":""},{"nctId":"NCT06195891","phase":"PHASE1","title":"Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-05-24","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":33},{"nctId":"NCT05507827","phase":"PHASE1","title":"Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2022-08-18","conditions":"Lymphoid Leukemia","enrollment":22},{"nctId":"NCT04013685","phase":"PHASE1","title":"Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orca Biosystems, Inc.","startDate":"2019-11-21","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes","enrollment":255}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Orca-T","genericName":"Orca-T","companyName":"Orca Biosystems, Inc.","companyId":"orca-biosystems-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Orca-T is a monoclonal antibody that targets the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}